topotecan has been researched along with Epithelial Neoplasms in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (6.67) | 18.2507 |
2000's | 11 (36.67) | 29.6817 |
2010's | 17 (56.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Murai, J | 1 |
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
Blank, SV; Curtin, J; Guddati, AK; Hochster, HS; Ivy, P; Joseph, B; Levinson, B; Muggia, F; Pothuri, B; Shapira, I; Stein, SM; Tiersten, A | 1 |
Barron, R; Chandler, DB; Fust, K; Li, X; Lyman, GH; Maschio, M; Parthan, A; Walli-Attaei, M; Weinstein, MC | 1 |
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
Chang Chien, CC; Fu, HC; Hu, CF; Lin, H; Ou, YC; Tsai, CC; Wu, CH | 1 |
Matsumoto, K; Onda, T; Yaegashi, N | 1 |
Annunziata, CM; James, J; Kim, MK | 1 |
Du, XL; Li, L; Shan, CP; Sheng, XG; Wei, P; Zhang, ZH | 1 |
Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T | 1 |
Anttila, M; Breda, E; Hanker, LC; Husain, A; Ojeda, B; Pujade-Lauraine, E; Vuylsteke, P; Wang, Y | 1 |
Leath, CA; Phippen, NT | 1 |
DeBernardo, RL; DeGeest, K; Herzog, TJ; Lentz, SS; Mutch, D; O'Malley, D; Shahin, M; Sill, MW; Walker, JL; Weiner, SA | 1 |
Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI | 1 |
Carter, JS; Downs, LS | 1 |
Bookman, MA | 2 |
Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
Kitao, A; Matsumoto, K | 1 |
Casado, A; Casado, MA; de Sande, LM; Merino, P; Ojeda, B | 1 |
Lane, SR; Ross, GA; ten Bokkel Huinink, W | 1 |
Apolone, G; Buda, A | 1 |
Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K | 1 |
Akman, L; Dikmen, Y; Goker, E; Karabulut, B; Ozsaran, A; Sanli, UA; Sezgin, C; Terek, MC; Uslu, R | 1 |
Camara, O; Fedders, M; Hartmann, M; Kath, R; Oelschläger, H; Schneider, A | 1 |
Abu-Ghazaleh, SZ; Argenta, PA; Bliss, RL; Boente, MP; Carson, LF; Chen, MD; Downs, LS; Geller, MA; Ghebre, R; Judson, PL; Nahhas, WA | 1 |
Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM | 1 |
Ozols, RF | 1 |
Bolis, G; Carmichael, J; Coleman, R; Davidson, N; Fields, SZ; Gordon, A; Gore, M; Héron, JF; Malfetano, J; Malmström, H; Ross, G; Scarabelli, C; Spaczynski, M; ten Bokkel Huinink, W; Vennin, P | 1 |
Crane, MM; Hunter, JE; Puls, LE | 1 |
4 review(s) available for topotecan and Epithelial Neoplasms
Article | Year |
---|---|
Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Cycle; Cisplatin; DNA Damage; DNA Repair; DNA Replication; DNA-Binding Proteins; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Topotecan | 2017 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
11 trial(s) available for topotecan and Epithelial Neoplasms
Article | Year |
---|---|
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Infusion Pumps; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Survival Analysis; Topotecan | 2013 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan | 2016 |
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2011 |
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Thalidomide; Topotecan | 2011 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan | 2004 |
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Thalidomide; Topotecan | 2008 |
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome | 1997 |
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate; Topotecan; United States | 2001 |
Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Time Factors; Topotecan; Treatment Outcome | 2002 |
15 other study(ies) available for topotecan and Epithelial Neoplasms
Article | Year |
---|---|
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Taxoids; Topotecan | 2014 |
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2015 |
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodiazepinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cisplatin; DNA Damage; DNA Repair; Drug Synergism; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinases; Pyrazoles; Topoisomerase I Inhibitors; Topotecan | 2015 |
Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Topotecan; Treatment Outcome | 2015 |
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult | 2015 |
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fatigue; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Thalidomide; Topotecan | 2009 |
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan | 2011 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan | 2012 |
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Doxorubicin; Drug Costs; Economics, Pharmaceutical; Female; Health Care Costs; Humans; Infusions, Intravenous; Liposomes; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Salvage Therapy; Spain; Topotecan | 2003 |
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Time Factors; Topotecan; Treatment Outcome | 2004 |
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Selection; Prospective Studies; Retrospective Studies; Topotecan | 2005 |
Topotecan in platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Survival Rate; Topotecan; Turkey | 2005 |
Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |